DICE Therapeutics, Inc. (DICE) Stock

About DICE Therapeutics, Inc.

DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics. Their flagship therapeutic asset is DC-806, an orally administered antagonist designed to inhibit interleukin-17, a pivotal pro-inflammatory signaling molecule widely recognized as a validated target across numerous immunology indications. Furthermore, DICE is advancing other oral treatment options, including therapies aimed at the α4β7 integrin for the management of inflammatory bowel diseases, and compounds targeting the αVβ1/αVβ6 integrin to treat idiopathic pulmonary fibrosis. Beyond these areas, the company also dedicates efforts to immuno-oncology, specifically developing antibody-based therapeutics. Established in 2013, DICE Therapeutics is headquartered in South San Francisco, California.

DICE Therapeutics, Inc. is headquartered in US.

DICE Therapeutics, Inc. (DICE) stock trades at $47.55 with a market capitalization of $2.27B. The stock is valued at a price-to-earnings (P/E) ratio of -22.97, price-to-book of -9.99, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $15.08 and $47.90, and currently trades at its 52-week high.

On profitability, DICE Therapeutics, Inc. generates a return on equity (ROE) of 56.07% — well above the market average, a sign of a high-quality business, return on capital employed of -15.24%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.dicemolecules.com